Cargando…
Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity
BACKGROUND: Galectin-3 (Gal-3), the only chimeric β-galactosides-binding lectin, consists of Gal-3N (N-terminal regulatory peptide) and Gal-3C (C-terminal carbohydrate-recognition domain). Interestingly, Gal-3C could specifically inhibit endogenous full-length Gal-3 to exhibit anti-tumor activity. H...
Autores principales: | Gao, Xiaoge, Jiang, Pin, Wei, Xiaohuan, Zhang, Wei, Zheng, Jiwei, Sun, Shishuo, Yao, Hong, Liu, Xiangye, Zhang, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930235/ https://www.ncbi.nlm.nih.gov/pubmed/36793021 http://dx.doi.org/10.1186/s12885-023-10608-9 |
Ejemplares similares
-
Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity
por: Gao, Xiaoge, et al.
Publicado: (2023) -
Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021) -
Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein
por: Ye, Qing, et al.
Publicado: (2012) -
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene
Publicado: (1994) -
Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)